Learn about common misconceptions on medical device risk and design controls.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Ho Chi Minh City Software Testing Conference January 2015
Software Testing in the Agile World
Website: www.hcmc-stc.org
Author: Lee Copeland
Over the years writers have defined testing as a process of finding, a process of evaluating, a process of measuring, a process of improving. For a quarter of a century we as testers have been focused on the internal process of testing, while generally disregarding its real purpose. The real purpose of testing is to create information. James Bach nailed it when he wrote, “The ultimate reason testers exist is to provide information that others on the project use to create things of value.” That is why testing exists — to provide information of value. So, when managers complain that testing “costs too much” perhaps they are really trying to say, “I’m not getting enough valuable information to justify the cost of testing.” When testers say “my management doesn’t see the value in our work” perhaps they are really trying to say, “My management doesn’t value the information I’m providing to them.” To prove our worth, to increase the value of testing, we must first focus on testing’s purpose — providing valuable information — not its process. Join Lee as he discusses why quantifying the value of testing is difficult work — perhaps that’s why we concentrate so much on testing process—that’s much easier. But until we do this difficult work, until we prove our worth through quantifying our contribution, we should expect the bombardments to continue.
In this advanced business analysis training session, you will learn User Stories from Scenarios. Topics covered in this session are:
• What is a Use Case?
• The Purpose of Use Case Analysis
• Managing the Building of Product
• The Basic Development Loop
• Analysis paralysis – how much is enough
• Conceptual model development
• Style Guide development
• Usability testing during agile increments
For more information, click here: https://www.mindsmapped.com/courses/business-analysis/advanced-business-analyst-training/
Anti-patterns for not-so-smart processes: Avoiding the BPM and SOA pitfalls. A short presentation to focus your project on success - featuring the "magic progress fairy"
How to increase conversion with usability testingDanny Setiawan
"We don't have time/budget to do usability testing." Sounds familiar? What if doing usability testing actually helps improve conversion? In this presentation, Danny shows how it directly affects conversion, how to do it and tools that professionals use.
At one time or another, every tester hears the dreaded question, “Why didn’t you guys catch these bugs?” We all have some standard responses, and they are most likely true). But what can we learn about our testing when we look beyond the easy answers? Pamela Gillaspie proposes that the key to improving your testing is determining the areas where bugs are slipping past your defenses. For her team, the practice is a lot like basketball. If you group the bugs into zones, you can devise a strategy to cover those zones more effectively. Some zones need a different testing approach than you’ve used; others might reveal a need for closer communication. Join Pamela as she shares her experience as defensive coordinator, addressing the developers’ playbook (What kinds of recurring problems do we see?), trick plays (The user is doing what?), and penalties (That wasn’t in the requirements!).
Ho Chi Minh City Software Testing Conference January 2015
Software Testing in the Agile World
Website: www.hcmc-stc.org
Author: Lee Copeland
Over the years writers have defined testing as a process of finding, a process of evaluating, a process of measuring, a process of improving. For a quarter of a century we as testers have been focused on the internal process of testing, while generally disregarding its real purpose. The real purpose of testing is to create information. James Bach nailed it when he wrote, “The ultimate reason testers exist is to provide information that others on the project use to create things of value.” That is why testing exists — to provide information of value. So, when managers complain that testing “costs too much” perhaps they are really trying to say, “I’m not getting enough valuable information to justify the cost of testing.” When testers say “my management doesn’t see the value in our work” perhaps they are really trying to say, “My management doesn’t value the information I’m providing to them.” To prove our worth, to increase the value of testing, we must first focus on testing’s purpose — providing valuable information — not its process. Join Lee as he discusses why quantifying the value of testing is difficult work — perhaps that’s why we concentrate so much on testing process—that’s much easier. But until we do this difficult work, until we prove our worth through quantifying our contribution, we should expect the bombardments to continue.
In this advanced business analysis training session, you will learn User Stories from Scenarios. Topics covered in this session are:
• What is a Use Case?
• The Purpose of Use Case Analysis
• Managing the Building of Product
• The Basic Development Loop
• Analysis paralysis – how much is enough
• Conceptual model development
• Style Guide development
• Usability testing during agile increments
For more information, click here: https://www.mindsmapped.com/courses/business-analysis/advanced-business-analyst-training/
Anti-patterns for not-so-smart processes: Avoiding the BPM and SOA pitfalls. A short presentation to focus your project on success - featuring the "magic progress fairy"
How to increase conversion with usability testingDanny Setiawan
"We don't have time/budget to do usability testing." Sounds familiar? What if doing usability testing actually helps improve conversion? In this presentation, Danny shows how it directly affects conversion, how to do it and tools that professionals use.
At one time or another, every tester hears the dreaded question, “Why didn’t you guys catch these bugs?” We all have some standard responses, and they are most likely true). But what can we learn about our testing when we look beyond the easy answers? Pamela Gillaspie proposes that the key to improving your testing is determining the areas where bugs are slipping past your defenses. For her team, the practice is a lot like basketball. If you group the bugs into zones, you can devise a strategy to cover those zones more effectively. Some zones need a different testing approach than you’ve used; others might reveal a need for closer communication. Join Pamela as she shares her experience as defensive coordinator, addressing the developers’ playbook (What kinds of recurring problems do we see?), trick plays (The user is doing what?), and penalties (That wasn’t in the requirements!).
Everyone has been given a 2 paragraph document listing the "scope of services" for a potential project. The client would like an estimate in 48 hours and there are no more details to help you deliver that required fixed bid contract. At the same time, many teams have also been given (or created) a detailed PRD or backlog document and still had a project budget balloon out of control. In this session I would like to discuss the not only the problems associated with estimation and how to avoid them, but more importantly how we can plan for them, turning our estimation process into not only an art, but a science. Well cover how to sell your estimate internally, and arm you with the methodologies to support your numbers. The problem with software estimation The morale The metrics The reality - an estimation metaphor Avoiding Risk Project entry point of sale At what point of the project lifecycle is your first sale? Risk association with point of sale Products in the front, estimations in the back The Elusive Discovery phase How to estimate a discovery How to sell a discovery How to include discovery in a full fixed bid RFP Planning for Risk Estimation types Gut - An art form Comparables - An art/science Factors/formula - A science Contingency Rating systems Formulas Granularity
Software Test Engineering - A guide to becoming successful testerAsim Kazmi
An slide deck for advising modern day software test engineering individuals on how to train your self to stay above the competition. Testing is not just automation or conformance with the requirements. Its much more than that and practicing the mentioned traits will help become a top notch testing professional.
Estimation - web software development estimation DrupalCon and DrupalCamp pre...Andy Kucharski
Project Estimation Presentation at DrupalCamps. Presentation discussing risks, methods and recommendations when estimating software estimation with a focus on web CMS (drupal)
Digital Transformation, Testing and AutomationTEST Huddle
The Digital Transformation is real. It is having a profound effect on how business is done and the nature of the systems required to deliver productive customer experiences and consequent business benefits.
Key Takeaways:
- What is the Digital Transformation and how does it affect testing?
- Some key findings from a recent and an ancient survey
- How to achieve testing and automation success.
To view the webinar, visit - http://testhuddle.com/resource/digital-transformation-testing-and-automation/
Effective Quality Facilitation | Beyond NormalSPIN Chennai
The presentation gives a glance on the software quality analysts who has to take up the full responsibility to ensure compliance. It inspires the analysts with different methods and examples for a successful delivery.
Software/Application Development EstimationJohn Nollin
Why as a software industry are we struggling so often with hitting our estimates? Does the problems reside in the way we are estimating a project or the way we are executing them? Through 30+ years of modern software development what have we learned and what are we continuing to struggle with today?
In this session I would like to discuss not only the problems associated with estimation and how to avoid them, but more importantly how we can plan for them, turning our estimation process into not only an art, but a science. Well cover how to sell your estimate internally, and arm you with the methodologies to support your numbers, and avoid the pitfalls that create projects that go 100% overbudget.
What is the problem with software estimation?
-- The morale, metrics and realities we have learned over time
-- The results of our decades worth of estimation error
Avoiding Risk
-- Project entry point of sale
-- Risk association with point of sale
-- Products in the front, estimations in the back
-- Getting out of jail
-- Other lessons learned
The Elusive Discovery phase
-- How to estimate a discovery
-- How to sell a discovery
Planning for Risk
-- Estimation types
--- Gut - An art form
--- Comparables - An art/science
--- Factors/formula - A science
-- Contingency
--- Rating systems
--- Formulas
---Granularity
This presentation explores the reasons why software projects are significantly more difficult to manage than other types of projects. Software-specific issues related to scope, resources, and time are explored, as well as how software projects differ from other projects in the physical world. An argument for why software constitutes a “Wicked Problem” is expanded, and numerous software development myths are attacked with real-world anecdotes and solutions.
The Compliance Concern: Challenges and Roadblocks for Ensuring Compliance in ...Greenlight Guru
The medical device industry is doubling down on compliance readiness. This is a significant shift from last year when we saw accelerating product development as the main goal. Ensuring compliance is a requirement for continued success, and most importantly, patient safety. The panelists will discuss the challenges device companies face as they manage compliance throughout the product lifecycle.
How Electronic Data Capture Is Transforming the MedTech IndustryGreenlight Guru
Clinical research is crucial to the life science industry. But did you know that medical device companies require a different approach? In this discussion, our panelists will talk about the challenges of clinical operations for MedTech, the benefits of leveraging MedTech-specific Electronic Data Capture (EDC) systems, the pitfalls of using outdated clinical data collection methods, such as paper, and much more!
More Related Content
Similar to Common Misconceptions on Medical Device Risk & Design Controls
Everyone has been given a 2 paragraph document listing the "scope of services" for a potential project. The client would like an estimate in 48 hours and there are no more details to help you deliver that required fixed bid contract. At the same time, many teams have also been given (or created) a detailed PRD or backlog document and still had a project budget balloon out of control. In this session I would like to discuss the not only the problems associated with estimation and how to avoid them, but more importantly how we can plan for them, turning our estimation process into not only an art, but a science. Well cover how to sell your estimate internally, and arm you with the methodologies to support your numbers. The problem with software estimation The morale The metrics The reality - an estimation metaphor Avoiding Risk Project entry point of sale At what point of the project lifecycle is your first sale? Risk association with point of sale Products in the front, estimations in the back The Elusive Discovery phase How to estimate a discovery How to sell a discovery How to include discovery in a full fixed bid RFP Planning for Risk Estimation types Gut - An art form Comparables - An art/science Factors/formula - A science Contingency Rating systems Formulas Granularity
Software Test Engineering - A guide to becoming successful testerAsim Kazmi
An slide deck for advising modern day software test engineering individuals on how to train your self to stay above the competition. Testing is not just automation or conformance with the requirements. Its much more than that and practicing the mentioned traits will help become a top notch testing professional.
Estimation - web software development estimation DrupalCon and DrupalCamp pre...Andy Kucharski
Project Estimation Presentation at DrupalCamps. Presentation discussing risks, methods and recommendations when estimating software estimation with a focus on web CMS (drupal)
Digital Transformation, Testing and AutomationTEST Huddle
The Digital Transformation is real. It is having a profound effect on how business is done and the nature of the systems required to deliver productive customer experiences and consequent business benefits.
Key Takeaways:
- What is the Digital Transformation and how does it affect testing?
- Some key findings from a recent and an ancient survey
- How to achieve testing and automation success.
To view the webinar, visit - http://testhuddle.com/resource/digital-transformation-testing-and-automation/
Effective Quality Facilitation | Beyond NormalSPIN Chennai
The presentation gives a glance on the software quality analysts who has to take up the full responsibility to ensure compliance. It inspires the analysts with different methods and examples for a successful delivery.
Software/Application Development EstimationJohn Nollin
Why as a software industry are we struggling so often with hitting our estimates? Does the problems reside in the way we are estimating a project or the way we are executing them? Through 30+ years of modern software development what have we learned and what are we continuing to struggle with today?
In this session I would like to discuss not only the problems associated with estimation and how to avoid them, but more importantly how we can plan for them, turning our estimation process into not only an art, but a science. Well cover how to sell your estimate internally, and arm you with the methodologies to support your numbers, and avoid the pitfalls that create projects that go 100% overbudget.
What is the problem with software estimation?
-- The morale, metrics and realities we have learned over time
-- The results of our decades worth of estimation error
Avoiding Risk
-- Project entry point of sale
-- Risk association with point of sale
-- Products in the front, estimations in the back
-- Getting out of jail
-- Other lessons learned
The Elusive Discovery phase
-- How to estimate a discovery
-- How to sell a discovery
Planning for Risk
-- Estimation types
--- Gut - An art form
--- Comparables - An art/science
--- Factors/formula - A science
-- Contingency
--- Rating systems
--- Formulas
---Granularity
This presentation explores the reasons why software projects are significantly more difficult to manage than other types of projects. Software-specific issues related to scope, resources, and time are explored, as well as how software projects differ from other projects in the physical world. An argument for why software constitutes a “Wicked Problem” is expanded, and numerous software development myths are attacked with real-world anecdotes and solutions.
Similar to Common Misconceptions on Medical Device Risk & Design Controls (20)
The Compliance Concern: Challenges and Roadblocks for Ensuring Compliance in ...Greenlight Guru
The medical device industry is doubling down on compliance readiness. This is a significant shift from last year when we saw accelerating product development as the main goal. Ensuring compliance is a requirement for continued success, and most importantly, patient safety. The panelists will discuss the challenges device companies face as they manage compliance throughout the product lifecycle.
How Electronic Data Capture Is Transforming the MedTech IndustryGreenlight Guru
Clinical research is crucial to the life science industry. But did you know that medical device companies require a different approach? In this discussion, our panelists will talk about the challenges of clinical operations for MedTech, the benefits of leveraging MedTech-specific Electronic Data Capture (EDC) systems, the pitfalls of using outdated clinical data collection methods, such as paper, and much more!
The ROI of Shifting Mindset From Compliance to QualityGreenlight Guru
Many MedTech companies focus on compliance without considering the importance of quality. In this session, panelists will dive into the differences between compliance vs. quality, the benefits of shifting mindset towards quality, and tips on how to start embedding quality into your organization.
Leveraging Modern Software Technologies: MedTech’s Best Kept SecretGreenlight Guru
There are several moving pieces that influence a medical device company’s time-to-market and continued success. An often overlooked (yet critical) one is the tools used to manage the product lifecycle. Are your tools working for you or slowing down your success? In this session, panelists will discuss trends from the 2023 survey results, common challenges with disjointed software solutions, the impact of modernizing, and the power of a modern QMS.
Behind the Stats: Expectations vs. Reality of Bringing a Device to MarketGreenlight Guru
Learn about what’s currently impacting the broader medical device industry. Our panelists will kick off the week by going over all the trends, statistics, and themes uncovered from the 2023 MedTech Industry Benchmark Survey. The session will uncover major shifts in industry goals, the use of modern Medtech software tools, major gaps in product lifecycle processes, and more. Discover how you can apply these findings as you make decisions within your organization in 2023 and beyond.
QMSR Harmonization: The Future of FDA's Quality Management System RegulationGreenlight Guru
Learn about the future of FDA's Quality Management System regulation.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Today we will discuss why a QMS is the backbone of Regulatory through the lens of ISO 13845. The presentation will cover the importance of starting a QMS early and ahead of a regulatory strategy.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Modernizing your QMS to keep up with the Modern Age of RequirementsGreenlight Guru
Learn about the importance of a modern QMS to keep up with changing requirements in the MedTech industry.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
In this session we will learn about the Why, the What, the Who, and the How for Medical Device Reporting to FDA through eMDR Submissions.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Moving up to the State of the Art in Risk ManagementGreenlight Guru
During this presentation we will explore where Medical Device Risk Management Systems are today. We will look at the quickly upcoming deadlines for implementing the ISO 14971:2019 3rd Edition, and EN ISO 14971:2019/A11:2021 standards. We will also mention the potential next (4th) edition of ISO 14971, and how the industry may influence the next edition.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
While ISO 13485 is written in black and white, the alignment between the standard's requirements and expectations is not always clear - especially in regards to SaMD (software as a medical device). This session will discuss aligning ISO 13485 with best practices for SaMD, and how we can expect the shift of the industry to impact the anchor standard of the medical device industry.
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Computer Software Assurance (CSA): Understanding the FDA’s New Draft GuidanceGreenlight Guru
Understand the FDA's new draft guidance on Computer Software Assurance (CSA).
This presentation originally aired during the 2022 Future of QMS Requirements Virtual Summit.
Making Headway Despite the Turbulence: Regulatory Requirements, Quality, and ...Greenlight Guru
The European Union’s In Vitro Diagnostic Medical Devices Regulation, or IVDR, became effective May 26, 2022. In this session, you’ll get a glimpse of what’s changed since implementation day, the latest guidance available, and ways to keep your IVDD to IVDR transition moving forward.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Reducing Friction Between Companies and Regulatory BodiesGreenlight Guru
We are operating in a complex environment, which is still undergoing changes. A lack of regulatory/quality management resources can be seen on both notified bodies and the industry. To overcome these hurdles, close collaboration and communication between companies and the notified body is necessary.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Latin American Regulations - What you Don't KnowGreenlight Guru
Central and South America are emerging as hot new Medical Device markets. These two subject matter experts in the area break down everything from regulatory advantages and ethical dilemmas.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Insights on the MedTech Regulatory and Clinical Environment in IsraelGreenlight Guru
Facts about the high-tech industry of Israel
The new medical device law in Israel
The regulatory landscape - requirements and market access
Performing clinical trials in Israel
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
The Global Guide to Human Factors and Usability Engineering RegulationsGreenlight Guru
The regulatory landscape related to human factors and usability engineering has continued to evolve since FDA issued its draft guidance for human factors over ten years ago. In fact, the international standard for usability engineering, IEC 62366-1: 2015 was amended as recently as 2020. The good news is that the pathway to a successful regulatory strategy, in terms of human factors and usability engineering, has never been more clear. The regulators have spoken, by way of guidance and standards documents, all that is left to do is to make sense of it all as it relates to your specific device or product.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Join industry expert, Danny Kroo, key takeaways from the session include: 1. What is MDSAP and when should you consider it? 2. How to prepare for an MDSAP certification audit 3. What are common nonconformities issued by auditing organizations
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
QMSR Harmonization - The Good the Bad and the UglyGreenlight Guru
Learn about the proposed QMSR rule, intended benefits of MDSAP for the regulatory authorities, benefits for the manufacturer, and similarities between ISO 13485 and FDA Regulations, and more!
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Unique Device Identification —aka UDI— is about more than barcodes and regulatory red tape. This global system for identifying medical devices is a chance to radically improve the quality of life for patients, providers, and producers of medical devices. However, implementing UDI into your product lifecycle means navigating differing requirements in both the United States and the European Union. If you’re looking to go global, we’ve brought together three industry leaders on the subject to make sure you know the difference.
This presentation originally aired during the 2022 Global MedTech Regulatory Trends Virtual Summit.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Common Misconceptions on Medical Device Risk & Design Controls
1. FINALLY, A NEXT-GEN CRO
Common Misconceptions
on Medical Device Risk &
Design Controls
www.ProximaCRO.com
2. Rob MacCuspie, Ph.D.
Quality & Regulatory Manager
rob.maccuspie@ProximaCRO.com
• Led 30+ medical device regulatory projects, including:
• 510(k)
• De Novo
• Pre-Submission meetings
• Breakthrough Device Designations
• Regulatory Strategies and Assessments
• EUA and Pre-EUA
• 513(g)
• Wellness devices
• Built Quality Management Systems from scratch
• 7+ years in medical device industry
• 7 years National Lab experience
• Florida Polytechnic University – First Faculty
• 45 peer reviewed publications – 3,800+ citations
Your Presenter Today
3. Common Misconceptions on Medical
Device Risk & Design Controls
Risk
• “Risks can be mitigated without having
completed that part of our QMS”
• “It’s so unlikely we don’t need to write that one
down”
• Reporting Risk Incorrectly - Jumping ahead on
Frequency
• Reporting Risk Incorrectly - Jumping ahead on
Severity
• One person can think of every risk
Design Controls
• “We can design now and wait to start our QMS”
• Design Controls must be perfect the first time
• Design Controls can never change
• Design Controls can always change
• Design Controls must be developed in a specific
order
• Not setting acceptance criteria or ranges
4. Poll #1
C
I’ve contributed to one or am working
on one now
A Never
Have you made a medical device risk matrix?
D I’ve contributed to many
B
I’ve reviewed them but not created
them
6. “Risks can be mitigated without having
completed that part of our QMS”
§ “Both and” thinking…
§ While true, risks can be identified and
mitigated even in the “back of the napkin”
ideation stage (and should!)…
§ If it isn’t documented in the QMS, it didn’t
happen
Every auditor
I’ve ever met:
7. “It’s so unlikely, we don’t need to write that one down”
• If it isn’t documented,
it didn’t happen
• Take credit for the
work you are doing
• Make the risk matrix
work for your device
• Can be 3x3, 4x4, or
5x5
8. Say what you do, do what you say
• Your team knows your device
better than anyone else
• What works for one device
may not work for another
device – make it work for your
device and company
• Risk tolerance, and Benefit-
Risk Analysis
9. Poll #2
C 5 x 5
A 3 x 3
What size risk matrix does your company use?
D We don’t have one, yet
B 4 x 4
10. Reporting Risks Incorrectly – Jumping Ahead on Frequency
Example #1: Push-Button Cover
Mitigation: Push-button cover
Result: Reduced frequency of
accidental button push
Where visionaries live How it started
§ Being a visionary, and connecting
dots others haven’t seen yet, is a
strength of founders and inventors
§ Risk analysis requires going back
to the current SOC, or the design
before the feature was added, and
walking readers through
11. Reporting Risks Incorrectly – Jumping Ahead on Severity
Example #2:
Sharp table corners
Reduced hazard severity from sharp corners
13. DESIGN CONTROLS
aka – Taking credit for all the hard work invested in designing this device
14. Poll #3
C
I’ve contributed to one or am working
on one now
A Never
Have you written medical device design controls?
D I’ve contributed to many
B
I’ve reviewed them but not created
them
Can include User Needs, Design Inputs, Design Outputs, Design Verification, Design Validation
15. “We can design now and wait to start
our QMS”
Every auditor I
haven’t met:
§ While true, design starts in the “back of the napkin”
ideation stage (and should!)…
§ If it isn’t documented in the QMS, it didn’t happen
§ Quality System compliance is required by law, under
21 CFR 820.
§ Delaying a QMS is a snowballing debt - if you don’t
do today’s work today, you have twice the work
tomorrow.
§ No Design Controls = No Device!
16. Design Controls have to be perfect the first time
§ Perfection is not required
§ Perfection is extremely rarely achieved the
first time…
§ To auditors, not documenting what you did to
get where you ended up likely means you
weren’t following your own documentation
controls – red flag to start digging deeply to
find what other controls were not being
followed
17. Design Controls have to be perfect the first time
§ Revisions show dedication to trying things
until they work
§ Design controls can be revised even after
design reviews, if data from verification or
validation reveals a need for design changes
§ Many examples of this happening
18. Design Controls can always change
§ At some point, you have to launch v1 and tell the
R&D team to keep those improvements for v2
§ Are you fixing v1 so it can launch, or making
a better v2?
§ Yes, it’s frustrating to have v2 ready and not
have it get to market for some time
§ Wouldn’t it be more frustrating to have v1
never launch and help patients, because
later v3 is delaying v2 and v1?
19. Design Controls must be developed in a fixed sequence
§ Yes, User Needs drive Design Inputs which
drive Design Outputs which drive Design
Verification
§ Teams may identify a single user need
then work through to the verification tests
§ Teams may identify all the user needs,
then all the design inputs, then all the
design outputs
§ Yes, Design REVIEWS generally follow a fixed
sequence
§ Assuming you SOPs allow…
§ A design review can be partial (e.g., some
user needs but not all)
§ A design review can be for all of one stage
(e.g., all user needs)
§ A design review can be for multiple stages
(e.g., all user needs and all design inputs)
20. Not setting acceptance criteria or ranges
§ How do you define success?
§ Why is that target acceptable?
§ Why is that range acceptable?
§ What data do you have, or need to
collect, to support this?
§ Not providing scientific justification
for the selections
21. Setting Acceptance Criteria Example
§ User need: fit through patient anatomy (say 5 mm)
§ What is the tolerance that is acceptable?
§ ±1µm? Clearly not from cost of manufacturing
§ ±1cm? Clearly not from anatomy requirements